BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

3918

524816

NATCOPHARM

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

NATCO PHARMA LTD. performance

Today’s low

Today’s high

₹ 848.60 ₹ 878.10
₹ 850.90

52 week low

52 week high

₹ 726.80 ₹ 1639.00
₹ 850.90

Open Price

₹ 878.05

Prev. Close

₹ 883.30

Volume (Shares)

707147.00

Total traded value

₹ 6017.11

Upper Circuit

₹ 1059.95

Lower Circuit

₹ 706.65

info

NATCO PHARMA LTD. Share Price Update

As of the latest trading session, NATCO PHARMA LTD. share price is currently at ₹ 850.9, which is down by ₹ -32.39 from its previous closing. Today, the stock has fluctuated between ₹ 848.60 and ₹ 878.10. Over the past year, NATCO PHARMA LTD. has achieved a return of -16.42 %. In the last month alone, the return has been 5.70 %. Read More...

NATCO PHARMA LTD. fundamentals


  • Market cap (Cr)

    15,240.46

  • P/E Ratio (TTM)

    8.60

  • Beta

    0.80

  • Book Value / share

    382.02

  • Return on equity

    25.38%

  • EPS (TTM)

    98.90

  • Dividend yield

    1.12%

  • Net profit/quarter (Cr)

    124.90

info icon alternate text
  • Market cap (Cr)

    15,241.36

  • P/E Ratio (TTM)

    8.60

  • Beta

    0.73

  • Book Value / share

    382.02

  • Return on equity

    25.38%

  • EPS (TTM)

    98.90

  • Dividend yield

    1.12%

  • Net profit/quarter (Cr)

    124.90

info icon alternate text

NATCO PHARMA LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 407.60
Operating Expense 425.29
Net Profit 124.90
Net Profit Margin (%) 30.64
Earnings Per Share (EPS) 6.97
EBITDA 197.40
Effective Tax Rate (%) 16.89
Particulars SEP 2024 (Values in Cr)
Revenue 1292.60
Operating Expense 547.10
Net Profit 661.10
Net Profit Margin (%) 51.14
Earnings Per Share (EPS) 36.91
EBITDA 842.10
Effective Tax Rate (%) 17.04
Particulars JUN 2024 (Values in Cr)
Revenue 1236.90
Operating Expense 518.69
Net Profit 636.30
Net Profit Margin (%) 51.44
Earnings Per Share (EPS) 35.53
EBITDA 802.80
Effective Tax Rate (%) 16.05
Particulars MAR 2024 (Values in Cr)
Revenue 964.80
Operating Expense 568.20
Net Profit 349.10
Net Profit Margin (%) 36.18
Earnings Per Share (EPS) 19.49
EBITDA 488.60
Effective Tax Rate (%) 19.28
Particulars DEC 2023 (Values in Cr)
Revenue 625.30
Operating Expense 431.20
Net Profit 192.00
Net Profit Margin (%) 30.70
Earnings Per Share (EPS) 10.72
EBITDA 267.80
Effective Tax Rate (%) 14.13
Particulars MAR 2024 (Values in Cr)
Revenue 3568.90
Operating Expense 2118.30
Net Profit 1306.60
Net Profit Margin (%) 36.61
Earnings Per Share (EPS) 72.79
EBITDA 1741.70
Effective Tax Rate (%) 15.99
Particulars MAR 2023 (Values in Cr)
Revenue 2351.00
Operating Expense 1665.80
Net Profit 637.10
Net Profit Margin (%) 27.09
Earnings Per Share (EPS) 34.90
EBITDA 930.20
Effective Tax Rate (%) 17.33
Particulars MAR 2022 (Values in Cr)
Revenue 1767.80
Operating Expense 1706.50
Net Profit 139.10
Net Profit Margin (%) 7.86
Earnings Per Share (EPS) 7.63
EBITDA 307.60
Effective Tax Rate (%) 10.77
Particulars MAR 2021 (Values in Cr)
Revenue 1653.50
Operating Expense 1362.39
Net Profit 309.50
Net Profit Margin (%) 18.71
Earnings Per Share (EPS) 16.99
EBITDA 518.70
Effective Tax Rate (%) 21.08
Particulars MAR 2020 (Values in Cr)
Revenue 1790.20
Operating Expense 1330.89
Net Profit 474.50
Net Profit Margin (%) 26.50
Earnings Per Share (EPS) 26.08
EBITDA 701.80
Effective Tax Rate (%) 18.62
Particulars MAR 2024 (Values in Cr)
Book Value / Share 326.99
ROE % 25.88
ROCE % 29.63
Total Debt to Total Equity 0.05
EBITDA Margin 47.00
Particulars MAR 2023 (Values in Cr)
Book Value / Share 267.06
ROE % 15.66
ROCE % 17.70
Total Debt to Total Equity 0.06
EBITDA Margin 38.42
Particulars MAR 2022 (Values in Cr)
Book Value / Share 233.62
ROE % 3.28
ROCE % 3.82
Total Debt to Total Equity 0.08
EBITDA Margin 16.44
Particulars MAR 2021 (Values in Cr)
Book Value / Share 225.84
ROE % 11.21
ROCE % 13.68
Total Debt to Total Equity 0.07
EBITDA Margin 34.59
Particulars MAR 2020 (Values in Cr)
Book Value / Share 207.34
ROE % 12.62
ROCE % 14.52
Total Debt to Total Equity 0.10
EBITDA Margin 36.03
Particulars MAR 2024 (Values in Cr)
Book Value / Share 312.42
ROE % 25.38
ROCE % 28.58
Total Debt to Total Equity 0.05
EBITDA Margin 48.80
Particulars MAR 2023 (Values in Cr)
Book Value / Share 257.64
ROE % 14.33
ROCE % 16.17
Total Debt to Total Equity 0.06
EBITDA Margin 39.57
Particulars MAR 2022 (Values in Cr)
Book Value / Share 229.69
ROE % 2.54
ROCE % 2.77
Total Debt to Total Equity 0.08
EBITDA Margin 14.98
Particulars MAR 2021 (Values in Cr)
Book Value / Share 224.17
ROE % 7.78
ROCE % 9.25
Total Debt to Total Equity 0.07
EBITDA Margin 31.37
Particulars MAR 2020 (Values in Cr)
Book Value / Share 212.61
ROE % 12.77
ROCE % 14.56
Total Debt to Total Equity 0.09
EBITDA Margin 39.20
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 952.90
Total Assets 6906.30
Total Liabilities 6906.30
Total Equity 5853.10
Share Outstanding 179109870
Price to Book Ratio 3.05
Return on Assets (%) 20.10
Return on Capital (%) 22.33
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 546.30
Total Assets 5657.40
Total Liabilities 5657.40
Total Equity 4873.80
Share Outstanding 182470115
Price to Book Ratio 2.19
Return on Assets (%) 12.64
Return on Capital (%) 14.2
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 206.10
Total Assets 5109.10
Total Liabilities 5109.10
Total Equity 4263.60
Share Outstanding 182337825
Price to Book Ratio 3.30
Return on Assets (%) 3.32
Return on Capital (%) 3.64
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 283.50
Total Assets 4791.90
Total Liabilities 4791.90
Total Equity 4123.40
Share Outstanding 182337825
Price to Book Ratio 3.68
Return on Assets (%) 9.20
Return on Capital (%) 10.05
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 66.00
Total Assets 4587.80
Total Liabilities 4587.80
Total Equity 3784.70
Share Outstanding 182067975
Price to Book Ratio 2.38
Return on Assets (%) 10.04
Return on Capital (%) 11.24
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 864.90
Total Assets 6554.00
Total Liabilities 6554.00
Total Equity 5592.30
Share Outstanding 179109870
Price to Book Ratio 3.05
Return on Assets (%) 19.93
Return on Capital (%) 21.94
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 412.00
Total Assets 5387.90
Total Liabilities 5387.90
Total Equity 4702.00
Share Outstanding 182470115
Price to Book Ratio 2.19
Return on Assets (%) 11.82
Return on Capital (%) 13.1
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 100.90
Total Assets 4978.00
Total Liabilities 4978.00
Total Equity 4191.90
Share Outstanding 182337825
Price to Book Ratio 3.30
Return on Assets (%) 2.79
Return on Capital (%) 3.04
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 262.80
Total Assets 4752.50
Total Liabilities 4752.50
Total Equity 4091.10
Share Outstanding 182337825
Price to Book Ratio 3.68
Return on Assets (%) 6.51
Return on Capital (%) 7.12
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 54.10
Total Assets 4646.70
Total Liabilities 4646.70
Total Equity 3869.50
Share Outstanding 182067975
Price to Book Ratio 2.38
Return on Assets (%) 10.21
Return on Capital (%) 11.34
Particulars MAR 2024 (Values in Cr)
Net Income 1673.50
Cash from Operations 1497.90
Cash from Investing -1032.70
Cash from Financing -246.90
Net change in Cash -68.00
Free Cash Flow 1837.30
Particulars MAR 2023 (Values in Cr)
Net Income 861.90
Cash from Operations 1026.60
Cash from Investing -477.10
Cash from Financing -363.00
Net change in Cash 9.00
Free Cash Flow 1172.89
Particulars MAR 2022 (Values in Cr)
Net Income 202.20
Cash from Operations 94.70
Cash from Investing -5.30
Cash from Financing 34.80
Net change in Cash 76.00
Free Cash Flow 327.50
Particulars MAR 2021 (Values in Cr)
Net Income 579.60
Cash from Operations 428.80
Cash from Investing -103.30
Cash from Financing -185.70
Net change in Cash 9.80
Free Cash Flow 683.40
Particulars MAR 2020 (Values in Cr)
Net Income 568.70
Cash from Operations 525.10
Cash from Investing -167.00
Cash from Financing -250.80
Net change in Cash -0.50
Free Cash Flow 880.80
Particulars MAR 2024 (Values in Cr)
Net Income 1555.30
Cash from Operations 1448.40
Cash from Investing -960.50
Cash from Financing -237.30
Net change in Cash -1.40
Free Cash Flow 1782.60
Particulars MAR 2023 (Values in Cr)
Net Income 770.70
Cash from Operations 932.80
Cash from Investing -436.60
Cash from Financing -346.80
Net change in Cash 1.00
Free Cash Flow 1075.30
Particulars MAR 2022 (Values in Cr)
Net Income 155.90
Cash from Operations 90.20
Cash from Investing -92.50
Cash from Financing 35.60
Net change in Cash 0.80
Free Cash Flow 315.70
Particulars MAR 2021 (Values in Cr)
Net Income 392.20
Cash from Operations 260.40
Cash from Investing -3.20
Cash from Financing -183.10
Net change in Cash -2.80
Free Cash Flow 500.29
Particulars MAR 2020 (Values in Cr)
Net Income 583.10
Cash from Operations 527.60
Cash from Investing -165.00
Cash from Financing -261.10
Net change in Cash -3.60
Free Cash Flow 880.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

NATCO PHARMA LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
850.90 -3.66 redarrow
red-green-graph indicator
10 Bearish
6 Bullish
  • 5 Days 867.50
  • 26 Days 844.00
  • 10 Days 856.00
  • 50 Days 892.10
  • 12 Days 851.60
  • 100 Days 1009.40
  • 20 Days 842.20
  • 200 Days 1095.70
886.03 PIVOT

First Support

871.77

First Resistance

897.57

Second Support

860.23

Second Resistance

911.83

Third Support

845.97

Third Resistance

923.37

RSI

51.38

ADX

22.31

MACD

7.63

Williams % R

-52.02

Commodity Channel Index (CCI)

66.36

Date

2025-04-30

Week

418583.00

Same Day

340557.00

Month

318218.00

1 Year

0.81

3 Year

0.61

Over 1 Month

5.70%

down

Over 1 Year

-16.42%

down

Over 3 Months

-26.76%

down

Over 3 Years

2.64%

down

Over 6 Months

-38.45%

down

Over 5 Years

6.85%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

NATCO PHARMA LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
27.29%
Promoter Holdings
49.56%
FII
17.49%
DII
5.64%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
V C Nannapaneni 2.8045905E7 (15.66%) Shareholding of Promoter and Promoter Group
Time Cap Pharma Labs Private Limited 1.717542E7 (9.59%) Shareholding of Promoter and Promoter Group
Venkata Satya Swathi Kantamani 1.593334E7 (8.9%) Shareholding of Promoter and Promoter Group
Natsoft Information Systems Pvt Ltd 1.57849E7 (8.81%) Shareholding of Promoter and Promoter Group
Belgrave Investment Fund 4145000.0 (2.31%) Public Shareholding
Life Insurance Corporation Of India Ltd 4094093.0 (2.29%) Public Shareholding
Vistra Itcl India Limited A/c Neelima Nannapaneni Trust 4082750.0 (2.28%) Shareholding of Promoter and Promoter Group
Durga Devi Nannapaneni 3539100.0 (1.98%) Shareholding of Promoter and Promoter Group
Tata Mutual Fund- Tata Equity P/e Fund 2268388.0 (1.27%) Public Shareholding
Akash Bhanshali 1800788.0 (1.01%) Public Shareholding
Rajeev Nannapaneni 1078000.0 (0.6%) Shareholding of Promoter and Promoter Group
Vistra Itcl India Limited A/c Durgadevi Family Trust 600000.0 (0.33%) Shareholding of Promoter and Promoter Group
T Anila 564920.0 (0.32%) Shareholding of Promoter and Promoter Group
Satya Vani Nannapaneni 420000.0 (0.23%) Shareholding of Promoter and Promoter Group
T Ananda Babu 413205.0 (0.23%) Shareholding of Promoter and Promoter Group
Vidyadhari Tummala 367200.0 (0.21%) Shareholding of Promoter and Promoter Group
Sanjay Nannapaneni 326910.0 (0.18%) Shareholding of Promoter and Promoter Group
Neelima Sita Nannapaneni 182960.0 (0.1%) Shareholding of Promoter and Promoter Group
Ndl Infratech Private Limited 93750.0 (0.05%) Shareholding of Promoter and Promoter Group
Tummala Jansi 77100.0 (0.04%) Shareholding of Promoter and Promoter Group
Kantamani Ratna Kumar 50000.0 (0.03%) Shareholding of Promoter and Promoter Group
Natco Aqua Limited 16000.0 (0.01%) Shareholding of Promoter and Promoter Group
Devendranth Alapati 15000.0 (0.01%) Shareholding of Promoter and Promoter Group
Sau Family Trust 1700.0 (0.0%) Shareholding of Promoter and Promoter Group
Vistra Itcl India Limited A/c Vcn Family Trust 1700.0 (0.0%) Shareholding of Promoter and Promoter Group
Bapineedu Tummala 415.0 (0.0%) Shareholding of Promoter and Promoter Group
Bapanna Alapati 0.0 (0.0%) Shareholding of Promoter and Promoter Group
Venkaiah Chowdary Nannapaneni Huf 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

NATCO PHARMA LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
26 Feb 2024 1.25 Interim 3 26 Feb 2024 Equity shares
24 Nov 2023 1.25 Interim 2 24 Nov 2023 Equity shares
22 Aug 2023 7.0 Interim 22 Aug 2023 Equity shares
21 Feb 2023 1.25 Interim 3 21 Feb 2023 Equity shares
21 Nov 2022 0.75 Interim 2 22 Nov 2022 Equity shares
19 Aug 2022 3.5 Interim 22 Aug 2022 Equity shares
24 Feb 2022 2.0 Interim 3 25 Feb 2022 Equity shares
23 Nov 2021 0.5 Interim 2 24 Nov 2021 Equity shares
24 Aug 2021 2.0 Interim 25 Aug 2021 Equity shares
22 Feb 2021 1.0 Interim 3 23 Feb 2021 Equity shares
24 Nov 2020 3.0 Interim 2 25 Nov 2020 Equity shares
21 Aug 2020 1.25 Interim 24 Aug 2020 Equity shares
26 Jun 2020 1.0 Interim 4 29 Jun 2020 Equity shares
24 Feb 2020 3.5 Interim 3 25 Feb 2020 Equity shares
21 Nov 2019 1.0 Interim 2 22 Nov 2019 Equity shares
22 Aug 2019 1.25 Interim 23 Aug 2019 Equity shares
06 Jun 2019 1.25 Interim 3 07 Jun 2019 Equity shares
21 Feb 2019 3.5 Interim 2 22 Feb 2019 Equity shares
20 Aug 2018 1.5 Interim 21 Aug 2018 Equity shares
15 Feb 2018 7.0 Interim 2 17 Feb 2018 Equity shares
16 Aug 2017 1.25 Interim 18 Aug 2017 Equity shares
23 Feb 2017 6.0 Interim 2 27 Feb 2017 Equity shares
19 Aug 2016 0.75 Interim 22 Aug 2016 Equity shares
22 Feb 2016 1.25 Interim 23 Feb 2016 Equity shares
24 Feb 2015 5.0 Interim 25 Feb 2015 Equity shares
24 Feb 2014 5.0 Interim 25 Feb 2014 Equity shares
22 Feb 2013 4.0 Interim 25 Feb 2013 Equity shares
22 Feb 2012 3.0 Interim 23 Feb 2012 Equity shares
24 Feb 2011 2.0 Interim 25 Feb 2011 Equity shares
05 Feb 2010 2.0 Interim 08 Feb 2010 Equity shares
04 Jun 2009 1.25 Interim 05 Jun 2009 Equity shares
12 Nov 2007 1.25 Interim 13 Nov 2007 Equity shares
10 Nov 2006 0.0 Interim 01 Jan 0001 Equity shares
10 Nov 2006 1.25 Final 13 Nov 2006 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
26 Nov 2015 10.0 2.0 28 Nov 2015
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
26 Feb 2024 1.25 Interim 3 26 Feb 2024 Equity shares
24 Nov 2023 1.25 Interim 2 24 Nov 2023 Equity shares
22 Aug 2023 7.0 Interim 22 Aug 2023 Equity shares
21 Feb 2023 1.25 Interim 3 21 Feb 2023 Equity shares
21 Nov 2022 0.75 Interim 2 22 Nov 2022 Equity shares
19 Aug 2022 3.5 Interim 22 Aug 2022 Equity shares
24 Feb 2022 2.0 Interim 3 25 Feb 2022 Equity shares
23 Nov 2021 0.5 Interim 2 24 Nov 2021 Equity shares
24 Aug 2021 2.0 Interim 25 Aug 2021 Equity shares
22 Feb 2021 1.0 Interim 3 23 Feb 2021 Equity shares
24 Nov 2020 3.0 Interim 2 25 Nov 2020 Equity shares
21 Aug 2020 1.25 Interim 24 Aug 2020 Equity shares
26 Jun 2020 1.0 Interim 4 29 Jun 2020 Equity shares
24 Feb 2020 3.5 Interim 3 25 Feb 2020 Equity shares
21 Nov 2019 1.0 Interim 2 22 Nov 2019 Equity shares
22 Aug 2019 1.25 Interim 23 Aug 2019 Equity shares
06 Jun 2019 1.25 Interim 3 07 Jun 2019 Equity shares
21 Feb 2019 3.5 Interim 2 22 Feb 2019 Equity shares
20 Aug 2018 1.5 Interim 21 Aug 2018 Equity shares
15 Feb 2018 7.0 Interim 2 17 Feb 2018 Equity shares
16 Aug 2017 1.25 Interim 18 Aug 2017 Equity shares
23 Feb 2017 6.0 Interim 2 27 Feb 2017 Equity shares
19 Aug 2016 0.75 Interim 22 Aug 2016 Equity shares
22 Feb 2016 1.25 Interim 23 Feb 2016 Equity shares
24 Feb 2015 5.0 Interim 25 Feb 2015 Equity shares
24 Feb 2014 5.0 Interim 25 Feb 2014 Equity shares
22 Feb 2013 4.0 Interim 25 Feb 2013 Equity shares
22 Feb 2012 3.0 Interim 23 Feb 2012 Equity shares
24 Feb 2011 2.0 Interim 25 Feb 2011 Equity shares
05 Feb 2010 2.0 Interim 08 Feb 2010 Equity shares
04 Jun 2009 1.25 Interim 05 Jun 2009 Equity shares
12 Nov 2007 1.25 Interim 13 Nov 2007 Equity shares
10 Nov 2006 0.0 Interim 01 Jan 0001 Equity shares
10 Nov 2006 1.25 Final 13 Nov 2006 Equity shares
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
26 Nov 2015 10.0 2.0 28 Nov 2015

NATCO PHARMA LTD. Share Price

Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs). The Company's focus is primarily on niche therapeutic areas and complex products. It sells products in over 40 countries. FDF products are sold in the United States, India, Europe and the rest of the world (RoW). Natco's API products are primarily used for captive consumption in its FDF products and are also sold to customers for various international markets such as Brazil, Europe and USA. In the API segment, Natco has capabilities to develop and manufacture products with multi-step synthesis, semi synthetic fusion technologies, high-potency APIs and peptides.

Natco Pharma is also engaged in contract manufacturing business, whereby the company undertakes selected contracts with pharmaceutical companies to manufacture and supply pharmaceutical products.

Natco Pharma was originally incorporated on 19 September 1981 as private limited company under the name of Natco Fine Pharmaceuticals Private Limited. It became a deemed public company with effect from 1 July 1992. The name of the company was changed to Natco Pharma Limited and a fresh certificate of incorporation consequent upon change of name was issued by the RoC, Andhra Pradesh on 18 February 1993. The company was converted into a public limited company and a fresh certificate of incorporation dated 30 December 1994 was issued by the RoC, Andhra Pradesh.

In 1988, the company inaugurated a Parenterals manufacturing facility at Nagarajuna Sagar, Telangana. In 1993, the company inaugurated its chemical division at Mekaguda, Telangana. On 1 April 1995, Natco Parenterals Limited, Natco Laboratories Limited and Dr. Karanth Pharma Labs Private Limited merged with Natco Pharma. In 1997, Natco Pharma inaugurated Natco Research Center (NRC) at Sanathnagar, Hyderabad.

In 2003, Natco Pharma launched its Oncology division with introduction of flagship brand VEENAT (generic Imatinib Mesylate) for the treatment of chronic myelogenous leukemia. In 2006, Natco Pharma inaugurated a world class finished dosage facility at Dehradun, Uttarakhand. In 2007, Natco Pharma launched its first abbreviated new drug application (ANDA) in the US market. During the year, the company acquired Savemart Pharmacy in USA.

In 2008, Natco Pharma filed its first Paragraph IV filing in the US market. In 2009, Natco Pharma's turnover reached $100 million milestone. In 2011, Natco Pharma and Levomed LLC, USA formed a joint venture company, Natcofarma Do Brasil for sales and distribution in Brazil.

In 2012, Natco Pharma won the first ever compulsory license from Bayer for its patent-protected anti-cancer drug Nexavar in India. During the year, the company established Natco Pharma Asia Pte Ltd as a wholly owned subsidiary for sales and distribution in Singapore.

In 2013, Natco Pharma established a subsidiary Natco Pharma Canada for sales and distribution in Canada. In 2014, Natco Pharma established a subsidiary Natco Pharma Australia Pty Ltd for sales and distribution in Australia.

On 9 March 2015, Natco Pharma announced that it has launched the first generic version of sofosbuvir in Nepal. Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc., under its brand Sovaldi. On 11 March 2015, Natco Pharma announced that it is the first company in India to get approval for generic sofosbuvir tablets, 400mg, from Drugs Controller General (India). Natco will market generic sofosbuvir under its brand HEPCINAT and through strategic partners in India.

The Board of Directors of Natco Pharma at its meeting held on 30 March 2016 approved the sale of its Save Mart Pharmacy Store located in the USA to CARE MART Inc. The Save Mart Pharmacy Store is owned by Natco Pharma Inc., a wholly owned subsidiary of the company, and is considered as a non-core part of the business.

On 12 December 2016, Natco Pharma announced the launch of the first generic version of Oseltamivir oral capsules, 30 mg, 45 mg and 75 mg through its marketing partner Alvogen in the USA market.

In 2017, Natco Pharma launched new cardiology and diabetology division for Indian market. On 2 January 2017, Natco Pharma announced that it has launched the first generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination is sold by Gilead Sciences, Inc., under brand name Epclusa. Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is also the first single tablet regimen approved for the treatment of patients with HCV genotype 2 and 3, without the need for Ribavirin.

On 17 May 2017, Natco Pharma announced that its partner Dr. Reddy's Laboratories Ltd. has received approval from the U.S. Food and Drug Administration (USFDA) to launch Doxorubicin Hydrochloride Liposome Injection, a therapeutic equivalent generic version of Doxil (doxorubicin hydrochloride liposome injection), for intravenous use, in the United States market.

On 5 October 2017, Natco Pharma announced that its marketing partner Mylan N.V., has launched in the U.S. the first Glatiramer Acetate Injection 40 mg/mL for 3-times-a-week injection that is an AP-rated substitutable generic version of Teva's Copaxone 40 mg/mL, as well as Glatiramer Acetate Injection 20 mg/mL for once-daily injection, an AP-rated, substitutable generic version of Teva's Copaxone 20 mg/mL. These products are indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS), a chronic inflammatory disease of the central nervous system. Shipments to customers have commenced.

On 4 November 2017, Natco Pharma announced that it has executed definitive agreement and subscribed to 7.50% of the paid-up equity share capital of OMRV Hospitals Private Limited (OMRV). The investment amount was Rs 7.50 crore. OMRV operates under brand name of PACE Hospital which is a super specialty hospital presently operating in Hyderabad, Telangana focused on tertiary care services in the field of Medical and Surgical Gastroenterology, Hepatology, Nephrology, Urology, GI Oncology and Andrology.

The Committee of Directors of Natco Pharma at its meeting held on 14 December 2017 approved allocation of 1 crore Equity Shares at the issue price of Rs 915 per Equity (including a premium of Rs. 913 per Equity Share) upon the closure of the issue, to eligible qualified institutional buyers pursuant to the QIP amounting to an Issue size of Rs 915 crore.

On 17 February 2018, Natco Pharma completed regulatory inspection from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad, India, which was conducted during the period 12th February, 2018 to 16th February, 2018, where the regulatory audit resulted in zero observations (no form 483 issued).

During FY 2019-20, NATCO had 8 launches in the domestic market, 5 in cardiology and diabetology segment, and 3 in oncology segment. It launched a combination drug Vildanat M (Vildagliptin and Metformin) for diabetes, to achieve better blood glucose control and improve therapy compliance.

During the period 2019-20, NATCO Life sciences Philippines Inc. was formed a fully owned subsidiary in the Philippines. During the year, it launched an FDC of Sofosbuvir-Daclatasvir tablets to treat Hepatitis C under the brand name 'Hepcinat Plus' and an oral fixed-dose combination of Sofosbuvir and Velapatasvir under their brand 'Velpanat'.

The Company has 7 subsidiaries as on March 31, 2020.

The Company has 7 international subsidiaries including 1 step-down subsidiary as on 31st March, 2021.

In FY 2020-21, the Company launched generic Lenalidomide in South Africa.

The Company has 8 international subsidiaries including 2 step-down subsidiaries as on 31st March, 2022.

During FY 2021-22, Company through NATCO Pharma Inc., USA a wholly owned Subsidiary of Company acquired Dash Pharmaceuticals LLC, USA effective on 1st January, 2022, where Dash Pharmaceuticals LLC, USA is a step-down wholly owned Subsidiary Company of the
Company. In Philippines, it launched first product, Liposomal Doxorubicin. In Australia, it received approval for Lenalidomide and Pomalidomide. It launched Sorafenib tablet in Taiwan with one year exclusivity. It launched first generic of Abiraterone tablets in Taiwan & Indonesia. It launched the Bendamustine Injection and Anastrozole tablets by the subsidiary named, Natco Lifesciences Philippines Inc. It launched the first generic of Oseltamivir in Brazil. It launched Everolimus in the US market. It launched 4 new products launched in 2021-22 such as Xpreza tablets, Pazonat, Cazanat and Tipanat for pateints suffering from liver, kidney and colorectal cancer.

11 new products launched in 2022-23. The Company launched Chlorantraniliprole (CTPR) pesticide formulation and its combination
products in liquid and granule forms. It launched a first generic alternative to the cancer drug Pomalidomide capsules sold under
the Pomalyst brand; launched Apixaban, Azacitidine in Philippines, Gefitinib, launched Oseltamivir capsules in the China market in 2023. It launched two Chlorantraniliprole (CTPR) pesticide formulation under brand names NATGEN and NATERRA and CTPR combination products under the brand names NATVOL and NATLIGO. It launched the first generic of Nat-Pomalidomide, Nat-Apixaban, and Nat-Teriflunomide in the market in the year 2023.

Parent organization Natco
NSE symbol NATCOPHARM
Founded 1981
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Natco Pharma Ltd?

Answer Field

The share price of Natco Pharma Ltd for NSE is ₹ 850.9 and for BSE is ₹ 850.95.

What is the Market Cap of Natco Pharma Ltd?

Answer Field

The market cap of Natco Pharma Ltd for NSE is ₹ 1,52,40.46 Cr. and for BSE is ₹ 1,52,41.36 Cr. as of now.

What is the 52 Week High and Low of Natco Pharma Ltd?

Answer Field

The 52 Week High and Low of Natco Pharma Ltd for NSE is ₹ 1639.00 and ₹ 726.80 and for BSE is ₹ 1638.35 and ₹ 660.05.

How to Buy Natco Pharma Ltd share?

Answer Field

You can trade in Natco Pharma Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Natco Pharma Ltd?

Answer Field

The 1 year returns on the stock has been -16.42%.

What is the Current Share Price of Natco Pharma Ltd?

Answer Field

Natco Pharma Ltd share price is for NSE ₹ 850.9 & for BSE ₹ 850.95 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Natco Pharma Ltd Share?

Answer Field

The market cap of Natco Pharma Ltd for NSE ₹ 1,52,40.46 & for BSE ₹ 1,52,41.36 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Natco Pharma Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Natco Pharma Ltd share is 8.60.

What is the PB ratio of Natco Pharma Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Natco Pharma Ltd share is 382.02.

How to Buy Natco Pharma Ltd Share?

Answer Field

You can trade in Natco Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Natco Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Natco Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Natco Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|